UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January 1~~ November 19, 2025

VASO CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware		0-18105		11-2871434
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

137 Commercial St., Suite 200, Plainview, New York 11803 (Address of Principal Executive Offices and Zip Code)

(~~Address~~516) of997-4600 ~~Principal~~Registrant’s ~~Executive~~Telephone ~~Offices~~Number, ~~and Zip~~Including Area Code)

Not Applicable (~~516)~~Former ~~997-4600~~Name or Former Address, if Changed Since Last Report)

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on which Registered

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Exchange Act (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 58.0201. ~~Departure~~Other ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~Events

~~(b)~~On &November ~~(c) Effective January 1~~19, 2025, ~~the~~Vaso ~~Board~~Corporation ofannounced ~~Directors appointed Jane Moen as~~ its ~~Chief~~agreement ~~Operating~~to ~~Officer. Mr. Peter C. Castle, previously Chief Operating Officer,~~sell ~~will~~its ~~continue in his capacity as President of the Company’s~~ wholly-owned subsidiary, ~~VasoTechnology,~~VasoHealthcare ~~Inc.~~IT MsCorp. ~~Moen,~~A ~~age~~press ~~45,~~release ~~has been~~announcing ~~a director of~~ the ~~Company~~transaction ~~since~~is ~~March~~attached ~~2020~~as ~~and~~Exhibit ~~an executive officer of the Company since 2018~~99. Ms1. ~~Moen has been President of the Company’s wholly-owned subsidiary, Vaso Diagnostics, Inc. d/b/a VasoHealthcare, since June 2018 and will continue in that capacity.~~

~~Effective~~Item ~~January 1, 2025, Michael Beecher, previously Co-Chief Financial Officer and Secretary, ceased serving in those roles but will continue to be employed by the Company as a financial advisor~~9.01. ~~As a result, Jonathan Newton, previously Co-Chief~~ Financial ~~Officer~~Statements and ~~Treasurer of the Company, continues as the company’s sole Chief Financial Officer and Treasurer and was also appointed as the Secretary of the Company.~~ Exhibits

1(d) Exhibits

SIGNATURE

99.1		November 19, 2025 Press Release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~1

~~Dated: January 3, 2025~~SIGNATURE

~~VASO~~Pursuant ~~CORPORATION~~to ~~By:~~the ~~/s/~~requirements of ~~Jun~~the MaSecurities ~~Name:~~Exchange ~~Jun~~Act Maof ~~Title:~~1934, ~~Chief~~the ~~Executive~~registrant ~~Officer~~has ~~and~~duly ~~President~~caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

2Dated: November 20, 2025

	VASO CORPORATION

	By:	/s/ Jun Ma
	Name:	Jun Ma
	Title:	Chief Executive Officer and President

Filing Compare · VASO Corp